Risk stratification of castration‑resistant prostate cancer patients treated with cabazitaxel

Kosaka,Takeo; Hongo,Hiroshi; Mizuno,Ryuichi; Oya,Mototsugu

doi:10.3892/mco.2018.1724

Risk stratification of castration‑resistant prostate cancer patients treated with cabazitaxel

Authors:
- Takeo Kosaka
- Hiroshi Hongo
- Ryuichi Mizuno
- Mototsugu Oya
View Affiliations

Affiliations: Department of Urology, Keio University School of Medicine, Tokyo 160‑8582, Japan
Published online on: September 19, 2018 https://doi.org/10.3892/mco.2018.1724
Pages: 683-688

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patient characteristics before administering the first cycle of cabazitaxel for metastatic castration‑resistant prostate cancer (mCRPC) were collected to assess prognostic factors for overall survival (OS). Multivariate analysis revealed that prostate‑specific antigen (PSA) ≥100 ng/ml prior to cabazitaxel treatment, visceral metastasis, and low absolute monocyte count were independent prognostic indicators for OS. The aim of the present study was to investigate prognostic biomarkers in patients treated with cabazitaxel among Japanese metastatic castration‑resistant prostate cancer (mCRPC) patients. In this retrospective study, 45 patients with mCRPC treated with cabazitaxel were reviewed retrospectively. Clinicopathological factors and laboratory data before administering the first cycle of cabazitaxel were collected to assess the prognostic factors for overall survival (OS). Treatment was generally well tolerated, with a median of 5 cycles (range, 1‑26). Median OS from the start of cabazitaxel treatment was 16.1 months (95% confidence interval 6.8‑25.5). Univariate analysis revealed that poor performance status, visceral metastasis, hemoglobin <11 mg/dl, absolute monocyte count <400/µl, and prostate‑specific antigen ≥100 ng/ml prior to cabazitaxel treatment (P=0.002) were significantly associated with shorter OS. Multivariate analysis revealed that PSA ≥100 ng/ml prior to cabazitaxel treatment, visceral metastasis, and absolute monocyte count <400/µl were independent prognostic indicators for OS. Based on the relative risk of death, patients with mCRPC before cabazitaxel therapy were divided into three risk groups: Low, intermediate, and high (P<0.001). In conclusion, the practical implications of our results may assist in tailoring the introduction of cabazitaxel.

View Figures

View References

1	Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK, Benard V, Henley SJ, Anderson RN, Fedewa S, et al: Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer. 124:2801–2814. 2018. View Article : Google Scholar : PubMed/NCBI
2	Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et al: Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 124:2785–2800. 2018. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
5	Akaza H, Onozawa M and Hinotsu S: Prostate cancer trends in Asia. World J Urol. 35:859–865. 2017. View Article : Google Scholar : PubMed/NCBI
6	de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 376:1147–1154. 2010. View Article : Google Scholar : PubMed/NCBI
7	Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, et al: Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 15:723–730. 2009. View Article : Google Scholar : PubMed/NCBI
8	Pivot X, Koralewski P, Hidalgo JL, Chan A, Gonçalves A, Schwartsmann G, Assadourian S and Lotz JP: A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 19:1547–1552. 2008. View Article : Google Scholar : PubMed/NCBI
9	Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS and Attard G: Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol. 66:459–465. 2014. View Article : Google Scholar : PubMed/NCBI
10	Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, et al: Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. 68:228–235. 2015. View Article : Google Scholar : PubMed/NCBI
11	Kosaka T and Oya M: Hemorrhagic cystitis in a patient without a past history of radiation therapy who was treated with cabazitaxel for CRPC. Ann Oncol. 26:2355–2356. 2015. View Article : Google Scholar : PubMed/NCBI
12	Watanabe K, Kosaka T, Hongo H, Tamaki S and Oya M: Headache caused by brain metastases of castration-resistant prostate cancer during cabazitaxel therapy. Keio J Med. 66:65–71. 2017. View Article : Google Scholar : PubMed/NCBI
13	Mukai H, Takahashi S, Nozawa M, Onozawa Y, Miyazaki J, Ohno K and Suzuki K: TED 11576 investigators: Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 73:703–710. 2014. View Article : Google Scholar : PubMed/NCBI
14	Nozawa M, Mukai H, Takahashi S, Uemura H, Kosaka T, Onozawa Y, Miyazaki J, Suzuki K, Okihara K, Arai Y, et al: Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol. 20:1026–1034. 2015. View Article : Google Scholar : PubMed/NCBI
15	Armstrong AJ, Garrett-Mayer E, Yang Ou YC, Carducci MA, Tannock I, de Wit R and Eisenberger M: Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 25:3965–3970. 2007. View Article : Google Scholar : PubMed/NCBI
16	Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I and Eisenberger M: Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 16:203–211. 2010. View Article : Google Scholar : PubMed/NCBI
17	Bando Y, Hinata N, Terakawa T, Furukawa J, Harada KI, Nakano Y and Fujisawa M: Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents. Med Oncol. 34:1632017. View Article : Google Scholar : PubMed/NCBI
18	Belderbos BPS, de Wit R, Hoop EO, Nieuweboer A, Hamberg P, van Alphen RJ, Bergman A, van der Meer N, Bins S, Mathijssen RHJ and van Soest RJ: Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel. Oncotarget. 8:106468–106474. 2017. View Article : Google Scholar : PubMed/NCBI
19	Uemura K, Miyoshi Y, Kawahara T, Ryosuke J, Yamashita D, Yoneyama S, Yokomizo Y, Kobayashi K, Kishida T, Yao M and Uemura H: Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel. BMC Cancer. 18:5012018. View Article : Google Scholar : PubMed/NCBI
20	Meisel A, von Felten S, Vogt DR, Liewen H, de Wit R, de Bono J, Sartor O and Stenner-Liewen F: Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. Eur J Cancer. 56:93–100. 2016. View Article : Google Scholar : PubMed/NCBI
21	Kosaka T, Shinojima T, Morita S and Oya M: Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel. Cancer Sci. 109:1570–1575. 2018. View Article : Google Scholar : PubMed/NCBI
22	Shigeta K, Kosaka T, Kitano S, Yasumizu Y, Miyazaki Y, Mizuno R, Shinojima T, Kikuchi E, Miyajima A, Tanoguchi H, et al: High absolute monocyte count predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Ann Surg Oncol. 23:4115–4122. 2016. View Article : Google Scholar : PubMed/NCBI